MedTrace Logo

Erector Spinae Block With Ropivacaine and Dexmedetomidine on Opioid Consumption After Lumar Spine Surgeries

NCT05664542 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2023-02-23

No results posted yet for this study

Summary

The aim of this study is to investigate the role of 0.5 micrograms/kg of dexmedetomidine with 0.2 % ropivacaine in erector spinae block in reducing opioid consumption for patients undergoing lumbar spine surgeries. This study will help in understanding the role of adding dexmdetomidine to ropivacaine in erector spinae block in reducing opioid consumption after lumbar spine surgeries

Conditions

  • Postoperative Pain

Interventions

OTHER

ESPB (regional Block)

ESPB is regional block in which we will use 0.2 % ropivacaine and dexmedetomidine

DRUG

ropivacaine and dexmedetomidine

0.2 % ropivacaine and dexmedetomidine

Sponsors & Collaborators

  • Security Forces Hospital

    lead OTHER

Principal Investigators

  • Anwar ul Huda, FRCA · Security Forces Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-12-15
Primary Completion
2023-04-30
Completion
2023-05-30

Countries

  • Saudi Arabia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05664542 on ClinicalTrials.gov